20xx中国国际医药高峰论坛上的演讲(ppt30中英文)-演讲技能(编辑修改稿)

20xx中国国际医药高峰论坛上的演讲(ppt30中英文)-演讲技能(编辑修改稿)内容摘要：

ector expanded at % CAGR. 19782020， 中国医疗产业年综合增长率为 % •Insurance coverage has increased 6X over the past five years and now covers 130 million people. 过去 5年内，保险覆盖率以 6倍速度增长， 目前已有 1亿 3千万人投保了保险 •19992020, total mercial health insurance premium grew at 48% CAGR, reaching $ billion. 19992020， 商业医疗保险保费收入年综合 增长率为 48%，达到 32亿美元 …is accelerating 加快 Life Science Cluster 生命科学集群 Bay Area: large IT/life science critical mass San Diego: entrepreneurial environment, global work North Carolina: presence of large anchor panies New Jersey: concentration of pharmaceutical panies Massachusetts: large number of worldclass hospitals Cambridgeshire: long research tradition Northern Europe: concentration of pharmaceuticals Israel: tight links with United States India: low labor cost, manufacturing expertise Singapore: large direct government investments Japan: large, relatively closed domestic market China: large domestic market, low research cost, strong government support SwissGerman: concentration of pharmaceuticals Established life science cluster Developing life science cluster 已建立的生命科学集群 发展中的生命科学集群 New clusters are developing globally 新集群在全球范围内发展 Shanghai上海 Shijiazhuang石家庄 Beijing北京 Changchun长春 Yangling杨凌 Kunming昆明 Shenzhen深圳 Guangzhou广州 Strong petition within China 中国市场竞争激烈 China’s Ramp。 D Advantage 中国的研发优势 • Access to large and highly qualified pool of researchers 拥有大批高素质研究人员 • Fast growing pool of overseas trained scientists 到海外接受培训的科学家与日俱增 • Positive government and public attitude towards Ramp。 D 政府和公众对研发的积极态度 • Large patient pool 大量的病人 • Low cost, quality and high speed 成本低，质量高，发展速度快 Low cost is not the most important factor低成本并非最重要的因素 Cost 成本 300 30 60 100 100% 20% 40% 50% Average Fully Loaded Cost per Full Time Equivalent (USD$’000) 全日制全面生产平均成本（ 1000美元） Price of a Typical Project (%) 项目的价格 (%) US 美国 China中国 Taiwan台湾 Singapore新加坡 Average costs parison for preclinical drug development 临床前药物开发平均成本比较 Intellectual Property Protection 知识产权保护 IP is the foundation of the life sciences industry Intellectual Property Protection Index (2020) 知识产权保护指数（ 2020） US美国 Singapore新加坡 Japan日本 India印度 China中国 知识产权保护是生命科学产业的基础 • IP laws are in place 知识产权相关法律已实施 • Data exclusivity and data protection 数据专属权与数据保护 • Promote actively IP achievements 积极扩大知识产权保护成果 The perception outside China is much worse than the reality inside China 国外认为中国知识产权保护薄弱，实际。